Dialybrid closed a €15 million Series A led by XGEN Venture to fund clinical and preclinical development of its hemodialysis vascular graft.
- Amount
- $17.2M
- Stage
- Series A
- Announced
- 22 September 2026
- Lead
- XGEN Venture
- Other investors
- CDP Venture Capital
- Use of funds
- Clinical development of the Silkothane graft for hemodialysis, and preclinical development of the material in other vascular applications.
- Checked
- Announced by the company